You are here

In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41RR028190-01
Agency Tracking Number: R41RR028190
Amount: $325,496.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCRR
Solicitation Number: PHS2010-2
Timeline
Solicitation Year: 2010
Award Year: 2010
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3181 SW SAM JACKSON PARK RD, L321
PORTLAND, OR 97239-3098
United States
DUNS: 801452249
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MARKUS GROMPE
 (503) 494-6888
 GROMPEM@OHSU.EDU
Business Contact
 HONGXIANG LAN
Phone: (503) 494-7784
Email: enotices@ohsu.edu
Research Institution
 Oregon Health And Science University
 
3181 SW Sam Jackson Pk Rd
PORTLAND, OR 97239-3098
United States

 () -
 Nonprofit college or university
Abstract

DESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules exists. Our company (Yecuris Inc.) has developed an in vivo genetic selection system (the FRG mouse) that permits extensive humanization of murine liver by transplanted human hepatocytes. Preliminary data show that highly humanized mice (gt80%) accurately reflect most aspects of human drug metabolism. Therefore highly humanized FRG mice are an attractive novel system for modeling human drug metabolism and pharmacokinetics at an early stage of drug development. However, the extent of liver humanization achieved in our mice currently remains highly variable, ranging from lt 5% to gt90%. In order to make our platform more attractive to commercial customers and more commercially viable (reduced production cost per mouse), it will be necessary to reproducibly achieve high humanization levels in the majority of mice. In this phase 1 STTR application we propose 2 specific aims to advance our goal of reliable liver humanization: 1) We will test different background strains of mice for their ability to support high level liver repopulation. 2) The effects of different regimens to deplete/inhibit hepatic Kupffer cells on repopulation levels will be ascertained. PUBLIC HEALTH RELEVANCE: The animal model is an attractive novel system for modeling human drug metabolism and pharmacokinetics at an early stage of drug development. Commercialization of our technology will greatly reduce the cost of and accelerate new drug development, thus contributing to public health.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government